Efficacy and toxicity of orally administrated anti-coccidial drugs for innovative treatments of Myxobolus sp. infection in Puntazzo puntazzo.

This study tested drugs and therapeutic compounds to determine effective commercial treatment for fishes infected with myxosporeans. Two series of shore-based experiments and 1 field trial were performed. For the shore-based experiments we used Puntazzo puntazzo (ca. 20 g weight) with kidneys infected with Myxobolus sp. Initially, 6 different doses of Fumagillin, 2 doses of Toltrazuril, and 1 dose of Amprolium, ESB3 and Salinomycin were tested. In the second shore-based experiment, infected fish were treated with Origanum essential oils, Toltrazuril with propylene glycol, Amprolium, and a combination of Salinomycin 12% + Amprolium (SA). In the field trial, P. puntazzo (ca. 165 g) infected with the parasite were treated with SA, Origanum essential oils and Fumagillin. In all trials, the drugs were added to the feed and administered according to the selected regimen. Their efficacy was evaluated in terms of mortality (acceptable level was <3%), pathology and prevalence rate of Myxobolus sp. Lesions were observed only in fish treated with Fumagillin and Toltrazuril. Pathology due to treatment with Fumagillin was observed only at doses > 6 mg kg(-1) body wt for 6 wk in the interstitial renal tissue, where slight inflammation arose. The highest dose tested (25 mg kg(-1)) also produced necrosis in the interstitial tissue, degeneration of the epithelial cells of the tubules and a reduction in melanomacrophage centre numbers. The SA combination proved the most effective treatment for Myxobolus sp. infection of P. puntazzo as (1) the therapeutic regimen and commercial product was not toxic and (2) a significant reduction occurred in the prevalence rate.

Toxicity and pathological effects of orally and intraperitoneally administered ivermectin on sea bass Dicentrarchus labrax.

The toxicity and histopathology of ivermectin was studied in 3 and 35 g sea bass Dicentrarchus labrax L. following in-feed, oral intubation and injection administration at dose rates ranging from 0.5 to 3.5 mg kg(-1). Estimated LD50 values for 3 g fish were 0.335 and 0.106 mg kg(-1) following oral intubation and injection administration respectively, for fish reared at 11 degrees C; and 0.839 and 1.023 mg kg(-1) following oral intubation and injection administration, respectively for fish reared at 20 degrees C. For 35 g fish reared at 11 degrees C, the estimated LD50 was 0.523 and 0.361 mg kg(-1) following oral intubation and injection administration respectively. No signs of toxicity were observed when the compound was administered via the feed at 0.5 and 0.7 mg kg(-1). However, toxicity (> 10%) was observed at dose rates of 0.2 mg kg(-1) and higher when the compound was administered via oral intubation and at 0.5 mg kg(-1) when administered via injection. The compound was significantly more toxic to fish reared at 11 degrees C than at 20 degrees C. Further, ivermectin was more toxic to 3 g than to 35 g sea bass when administered via injection. Histopathological examination of the major organs revealed pathology was largely restricted to gills and intestinal tissue. In 3 g sea bass, lesions were also found in the kidneys.